雷替曲塞或氟尿嘧啶联合伊立替康二线治疗晚期结直肠癌的疗效分析
Analysis of efficacy of pemetrexed or fluorouracil combined with irinotecan in the treatment of advanced colorectal cancer
吕海栋 1本巴吉 2刘国庆 2朱智勇 2陶飞 2徐建国 2储怀祝2
作者信息
- 1. 青海省人民医院 肿瘤外科,青海 西宁 810007
- 2. 青海省人民医院 肿瘤内科,青海 西宁 810007
- 折叠
摘要
目的 研究雷替曲塞或氟尿嘧啶联合伊立替康二线治疗晚期结直肠癌的疗效.方法 选择2014年1月~2016年1月青海省人民医院收治的晚期结直肠癌患者68例,采用随机分组的方法分为对照组和观察组,每组纳入患者34例.对照组患者采用氟尿嘧啶联合伊立替康的方法进行二线治疗,观察组患者采用雷替曲塞联合伊立替康的方法进行二线治疗.治疗后,对比2组患者的治疗效果、不良反应、生存状况.结果 观察组患者治疗总有效率为38.24%,高于对照组患者的8.82%,差异具有统计学意义(P<0.05);观察组患者疾病控制率为76.47%,高于对照组患者的52.94%,差异具有统计学意义(P<0.05).观察组患者发生不良反应的几率为200.00%,低于对照组患者的305.88%(P<0.05).观察组患者无进展生存时间为(6.81±2.31)月,高于对照组患者的(3.75±1.06)月,差异具有统计学意义(P<0.05);观察组患者总生存时间为(14.69±4.28)月,高于对照组患者的(8.76±2.27)月(P<0.05).结论 在晚期结直肠癌二线治疗中,使用雷替曲塞联合伊立替康进行治疗,能够提高治疗总有效率和疾病控制率,减少不良反应,延长患者生存时间.
Abstract
Objective To study the efficacy of pemetrexed or fluorouracil in combination with irinotecan in the treatment of advanced colorectal cancer. Methods 68 patients with advanced colorectal cancer were selected from January 2014 to January 2016 in Qinghai Provincial People's hospital. Patients were divided into the control group and the observation group by random grouping, and 34 patients for each group. Patients in the control group were received second-line therapy with fluorouracil and irinotecan. The patients in the observation group were received second-line therapy with the combination of pemetrexed and irinotecan. After treatment, the treatment effects, adverse reactions and living conditions of two groups were compared. Results The total effective rate of the observation group was 38.24%, was higher than that of the control group 8.82% (P<0.05); the observation group's disease control rate was 76.47%, was higher than that of the control group 52.94% (P<0.05). The incidence of adverse reactions in the observation group was 200.00%, which was lower than 305.88% in the control group (P<0.05). Progression free survival time in the observation groupwas (6.81±2.31) months, was higher than the control group (3.75±1.06) months (P<0.05); the total survival time in the observation group was (14.69±4.28) month, was higher than the control group (8.76±2.27) month (P<0.05). Conclusion In the second-line treatment of advanced colorectal cancer, the application of raltitrexed combined with irinotecan treatment, could improve the total efficiency of treatment and disease control rate, reduce adverse reactions, and prolong the survival time of patients.
关键词
雷替曲塞/氟尿嘧啶/伊立替康/二线治疗/晚期结直肠癌Key words
pemetrexed/fluorouracil/irinotecan/second-line therapy/advanced colorectal cancer引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据